Literature DB >> 12468261

Induction of thromboxane A2 synthesizing enzymes in DMSO-induced granulocytic differentiation of HL-60 cells.

M Zaitsu1, E Ishii, Y Hamasaki.   

Abstract

Human leukemia (HL)-60 cells were differentiated by several agents, and prostaglandins (PGs) and thromboxane (TX) synthesizing activity increased in response to the differentiation of the cells. We examined the expression of messenger RNA (mRNA) for TX-synthesizing enzymes, cyclooxygenase (COX)-1, COX-2 and TXA(2) synthase, in dimethyl sulfoxide (DMSO)-differentiated HL-60 cells by reverse transcriptase polymerase chain reaction (RT-PCR), and A23187-stimulated TXB(2) production, a stable metabolite of TXA(2), by radioimmunoassay (RIA). A23187-stimulated TXB(2) production, and mRNA abundance for COX-2, were not detected in non-treated HL-60 cells. TXA(2) synthase mRNA were barely detected in non-treated HL-60 cells. DMSO-induced HL-60 cells gained induction of TXB(2) synthesis and mRNA for COX-2 and TXA(2) synthase during granulocytic differentiation. COX-1 mRNA was constitutively expressed. A23187-stimulated TXB(2) production in DMSO-treated cells was inhibited by NS-398, a specific COX-2 inhibitor. These results demonstrated that TXB(2) production in granulocytic HL-60 cells was regulated at both the enzyme level of COX-2 and TXA(2) synthase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468261     DOI: 10.1054/plef.2002.0450

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  2 in total

1.  Optimization of cell-based assays to quantify the anti-inflammatory/allergic potential of test substances in 96-well format.

Authors:  C V Chandrasekaran; R Edwin Jothie; Preeti Kapoor; Anumita Gupta; Amit Agarwal
Journal:  Inflammopharmacology       Date:  2010-10-31       Impact factor: 4.473

2.  Lipid mediators and human leukemic blasts.

Authors:  Rémi Fiancette; Christelle Vincent-Fabert; Estelle Guerin; Franck Trimoreau; Yves Denizot
Journal:  J Oncol       Date:  2010-10-10       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.